The 2014 Mayo Approach to the Management of HCM and Non-Compaction

Similar documents
The Management of Hypertrophic Cardiomyopathy

Managing Hypertrophic Cardiomyopathy with Imaging. Gisela C. Mueller University of Michigan Department of Radiology

Interventional Imaging Cases

Managing the Low Output Low Gradient Aortic Stenosis Patient

Steel vs Alcohol. Or Neither. Management of Hypertrophic Cardiomyopathy. Josh Doll, MD January 24, 2015

Medical Policy and and and and

The Management of HOCM: What are the Surgical Options

Hypertrophic Cardiomyopathy: Patient Management in 2018

Treatment of Hypertrophic Cardiomyopathy in Bruce B. Reid, MD

Alcohol Septal Abla-on: Is This Now First Line Treatment for Hypertrophic Obstruc-ve Cardiomyopathy (HOCM)?

Update on Evaluation and Nonsurgical Treatment Strategies for the Symptomatic Patient with HCM

Left ventricular outflow tract obstruction: indications and limitations of current therapies

Anaesthesia for non-cardiac surgery in patients left ventricular outflow tract obstruction (LVOTO)

marked increase in thickness of walls of heart in patient with HCM.

HOCM: Alcohol ablation or LVOT Surgery: When and what?

Management of HOCM: Non-Surgical Options

Barry J. Maron, MD Hypertrophic Cardiomyopathy Institute Tufts Medical Center Boston, MA. Disclosures: Medtronic (Grantee) GeneDx (Consultant)

Cardiac Issues in the Adolescent Athlete. Sean Levchuck, M.D. St. Francis Hospital- The Heart Center

Hypertrophic Cardiomyopathy: basics and management

Hypertrophic Cardiomyopathy: beyond gradient and wall thickness

HYPERTROPHIC CARDIOMYOPATHY: Severe Heart Failure. Paolo Spirito, Genoa, Italy

What s new in Hypertrophic Cardiomyopathy?

Cases in Stress Echo DISCLOSURE

Cardiomyopathy. Cardiomyopathies HOCM. Hypertrophic Obstructive Cardiomyopathy. Systolic Anterior Movement (SAM) of Mitral Valve (Venturi Effect) Cine

Cardiac MRI: Cardiomyopathy

Diastolic Heart Failure

Utility of Echocardiography

Echocardiographic Evaluation of the Cardiomyopathies. Stephanie Coulter, MD, FACC, FASE April, 2016

Case based learning: CMR in Heart Failure

Cardiomyopathy: The Good, the Bad.and the Insurable?

Diastolic Function Assessment Practical Ways to Incorporate into Every Echo

Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy. CardioVascular Research Foundation

Cardiomyopathy. Jeff Grubbe MD FACP, Chief Medical Director, Allstate Life & Retirement

In the Thick of It: Hypertrophic Cardiomyopathy

Case Presentation: A 58-yearold

ORIGINAL PAPER. R. C. Steggerda & J. C. Balt & K. Damman & M. P. van den Berg & J. M. ten Berg

Etiology, Classification & Management. Sheba Medical Center Cardiology Department Matthew Wright St. George s University of London

Surgical Myectomy for HOCM

Left ventricular non-compaction: the New Cardiomyopathy on the Block

December 2018 Tracings

The use of Cardiac CT and MRI in Clinical Practice

Hypertrophic Cardiomyopathy

Highlights from EuroEcho 2009 Echo in cardiomyopathies

Restrictive Cardiomyopathy

HEART CONDITIONS IN SPORT

EVALUATION OF THE ATHLETE. Karen Stout, MD Professor, Medicine and Pediatrics University of Washington

Nancy Goldman Cutler, MD Beaumont Children s Hospital Royal Oak, Mi

2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy

NON-INVASIVE TREATMENT OPTIONS IN HYPERTROPHIC CARDIOMYOPATHY

3/17/2014. WS # 3 ICD Registry Case Scenarios with Structural Abnormalities. Objectives. Denise Pond BSN, RN

Case based learning: CMR in Heart Failure

TSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD

Aortic Valvular Stenosis

Dobutamine Stress testing In Low Flow, Low EF, Low Gradient Aortic Stenosis Case Studies

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD

Hypertrophic Cardiomyopathy. Sean Sliman PGY4 2/7/2017

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Choose the grading of diastolic function in 82 yo woman

Index of subjects. effect on ventricular tachycardia 30 treatment with 101, 116 boosterpump 80 Brockenbrough phenomenon 55, 125

Mitral Valve Prolapse and Sudden Death. JF Avierinos Hôpital Timone Marseille January 27th, 2017

Cardiomyopathies. Andre Keren, MD

New Therapies for the Heart Patient. Wilson They said "There's nothing more that can be done." Robert Federici MD, Presbyterian Heart

Tachycardia Devices Indications and Basic Trouble Shooting

Conflict Disclosures. Vermont Cardiac Network. Outline. Series Learning Objectives 4/27/2016. Scott E. Friedman April 28, 2016

Diastolic Function Assessment New Guideline Update Practical Approach

Low Gradient AS Normal LVEF

Candice Silversides, MD Toronto Congenital Cardiac Centre for Adults University of Toronto Toronto, Canada

Valvular Heart Disease. Dr. HANAN ALBACKR

Heart Valve disease: MR. AS tough patient When to echo, When to refer, What s new

Diastolic Heart Function: Applying the New Guidelines Case Studies

Slide 1. Slide 2. Slide 3. Sudden Cardiac Death In Athletes. Epidemiology. Epidemiology. Shaun McMurtry, MD Primary Care Sports Medicine

Septal Myectomy, Papillary Muscle Resection, and Mitral Valve Replacement for Hypertrophic Obstructive Cardiomyopathy: A Case Report

Detailed Order Request Checklists for Cardiology

How NOT to miss Hypertrophic Cardiomyopathy? Adaya Weissler-Snir, MD University Health Network, University of Toronto

HYPERTROPHIC CARDIOMYOPATHY RISK STRATIFICATION WHAT IS NEW?

Cases in Adult Congenital Heart Disease

Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know

Sudden Death in Athletes: What is the role of ECG Screening?

Endurance Exercise and Cardiovascular Health

HCM GUIDELINES ESC 2014 HYPERTROPHIC CARDIOMYOPATHY ASYMPTOMATIC PATIENT

Ve V rmont rmon Card Car iac d Netw Ne ork tw Scott E. Friedman April 28, 2016

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Cardiomyopathy Consequences. function of the myocardium for any reason. This is a serious disease in which the heart muscle

Pericardial Disease: Case Examples. Echo Fiesta 2017

Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ;

4/11/2017. Cardiomyopathy. John Steuter, MD Bryan Heart. Disclosures. No Conflicts. Cardiomyopathy. WHO Classification

ESC Guidelines on Hypertrophic Cardiomyopathy

P F = R. Disorder of the Breast. Approach to the Patient with Chest Pain. Typical Characteristics of Angina Pectoris. Myocardial Ischemia

Cardiology. the Sounds: #7 HCM. LV Outflow Obstruction: Aortic Stenosis. (Coming Soon - HCM)

Hypertrophic Obstructive Cardiomyopathy

Asymptomatic Valvular Disease:

Physical Exam Part II

HCM: The Tip Of The Iceberg. HCM Is A Global Disease. Unidentified. 50 countries.all continents. Rural Minnesota N=15,137;16-87 y 0.

CARDIOMYOPATHY IN CT. Hans- Christoph Becker Professor of Radiology


Why Cardiac MRI? Presented by:

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Percutaneous Mitral Valve Repair

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Transcription:

The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-1

Let s start with a case 52 y/o man Class III DOE Loud murmur 300 mg lopressor Gradient 100 mmhg CP1288794-2

Next step? 1. More meds 2. Dual chamber PM 3. Septal ablation 4. Septal myectomy 5. AICD CP1288794-3

Treatment of HCM Relieve Symptoms Prevent Sudden Death Dynamic LVO Obstruction CP1288794-4

Relieve obstruction Improve diastolic filling Reduce MR Improve symptoms Gradient LAP CP1288794-5

Hypertrophic Cardiomyopathy Medical therapy : symptomatic pt Intolerant Beta Blockers Ca Blockers Intolerant Disopyramide Continued symptoms Myectomy DDD pacing Ablation CP1288794-6

Dual Chamber Pacing NSR PACE CP980117-19 CP1288794-7

New medicines and other cures always work miracles for awhile William Heberden 1877 CP1288794-8

Hypertrophic Cardiomyopathy Dual chamber pacing update 2014 Placebo effect wears out 6 months Overall improvement < 30% patients Possible detrimental effect Long-term pacing : myocardial dysfunction Mayo data CP1288794-9

Septal Reduction Therapy CP1288794-10

Septal Reduction Therapy Septal Myectomy CP1288794-11

Surgical septal myectomy for symptomatic HOCM is safe and effective In the hands of experienced surgeons Operative mortality 0.8% Gradient 3 mm Post-op NYHA 1-2 94% CP1288794-12

Septal Myectomy: Mayo Data 100 256 pts F/U 10 yrs 80 % Pts 60 40 I-II III-IV 20 0 Before Postop CP1288794-13

Myectomy and Survival 1.0 0.9 Nonobstructive Myectomy (Mayo) Overall survival 0.8 0.7 0.6 Same results for cardiac survival and sudden death Nonoperated obstructive P<0.001 0.5 0 2 4 6 8 10 Ommen et al: JACC, 2005 Years CP1160937-13 CP1288794-14

Hypertrophic Cardiomyopathy It is clear that surgical myectomy will result in marked long-lasting symptomatic improvement in over 90% of patients with severe symptoms and obstruction CP1288794-15

Septal Ablation The New Kid on the Block A localized heart attack CP1288794-16

Septal Ablation CP1288794-17

Hypertrophic Cardiomyopathy 150 mm Hg 150 mm Hg 0 mm Hg Baseline 0 mm Hg After ablation CP980117-28 CP1288794-18

Surgery now has no role in the management of HCM Ablation is the new gold standard for the 21 st century Myectomy is only an impediment to the development of alcohol ablation Heart 2006:92:1339 JACC 2004:44:2054 Br J Card 2006:13:58 CP1288794-19

Septal Ablation Success rate Structural Anatomy Anatomy Coronaries CP1288794-20

No Systolic Anterior Motion of Mitral Valve Ablation ineffective Fixed subaortic stenosis 8-10% of referrals CP1288794-21

MR jet directed anteriorly Ablation ineffective Flail leaflet 7-8% CP1288794-22

Septal Ablation Success Structural Anatomy Anatomy Coronaries CP1288794-23

Septal perfusion: just right CP1288794-24

Septal perfusion: too much CP1288794-25

Septal perfusion:?????? CP1288794-26

Septal Ablation There are a subgroup of patients in whom the targeted septum cannot be reached by septal perforators CP1288794-27

Septal myectomy Pre Post CP1288794-28

Septal ablation Pre Post CP1288794-29

Septal Ablation Complicatons Short Term Follow-up CP1288794-30

Complete Heart Block (10-18%) CP1288794-31

Ventricular Fibrillation Incidence unknown Sudden unexpected CP1288794-32

Septal Ablation Other acute complications Coronary dissection: 0-2.5% (1.8%) Large infarction:???? Tamponade:.8-5% (3%) Stroke: 1.1% Nagueh JACC 2001 Faber EJE 2004 Fernandez JACC CV Int 2008 Firoozi EHJ 2002 Qin JACC 2001 Ralph-Edwards JTCVS 2005 Alam J int C 2006 Baggish Heart 2006 CP1288794-33

This needs to be done in an experienced center!!!! 25 y/o Ablation done Now on transplant list CP1288794-34

Septal Ablation Clinical Outcome CP1288794-35

Survival without Severe Sx Pts aged <65 yrs 100 80 Myectomy 90% 60 40 Ablation p=0.02 71% 20 0 No. at risk Myectomy 72 69 61 50 Ablation 52 37 24 18 0 1 2 3 4 Sorajja et al, Circ 2008 Follow-up (yrs) CP1286515-6 CP1288794-36

Septal Ablation 4 yr survival free of death, NYHA Class III/IV or myectomy : 76% 1 of 4 will not have benefit CP1288794-37

Ablation Myectomy Elderly Co-morbidities Limited life-span Sedentary Younger Healthy Long life-span Active CP1288794-38

Patients/year 250 Septal Reduction Therapy Mayo Clinic 200 150 100 Myectomy Ablation 50 0 1973 1978 1983 1988 1993 1998 2003 2008 2013 Year CP1288794-39

Treatment of HCM Relieve Symptoms Prevent Sudden Death CP1288794-40

Can we identify those patients at risk for sudden death? CP1288794-41

Risk Factors for Sudden Death Really Bad Arrest Sustained VT Bad FH HCM and Sudden death LVH > 30 mm Unexplained syncope Somewhat Bad NSVT BP drop TMET Gadolinium DE LVO CAD CP1288794-42

AICD: Caveats 72 y/o with four episodes syncope over 5 years 18 y/o with one episode syncope 1 week ago CP1288794-43

Let s finish with a case LV RV 54 y/o woman Atypical chest pain Normal exam CP1288794-44

What would you do? 1. Right and left heart cath / bx 2. Observation only 3. AICD 4. Anticoagulation 5. Surgery CP1288794-45

Noncompaction of the myocardium A failure of the normal embryologic development of the heart Myocardium noncompacted (ratio 2:1 of trabeculated to solid) Early studies High rate of sudden death, stroke, etc CP1288794-46

Noncompaction Wide spectrum of prognosis Benign Malignant Systolic function Symptoms Family history CP1288794-47

Noncompaction Wide spectrum of prognosis Benign Malignant Observe Reassure AICD Anticoagulation CP1288794-48

The 2014 Mayo Approach to the Management of HCM and Non-Compaction R A Nishimura MD MACC MACP Judd and Mary Morris Leighton Professor Mayo Clinic No disclosures or conflict of interest CP1288794-49